ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
The Genomic Landscape of
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 214 papers.
0numbers the graph read from it
0cells of the map it votes in
214citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
214 citing papers in PubMed, 273 citations in OpenAlex.
- A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort.Cancer communications (London, England) · 2025Trial
- SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024Trial
- Clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboringAnnals of medicine · 2026Article
- Skeletal Muscle Metastasis in Patients With SMARCA4-Deficient Thoracic Tumors: A Retrospective Cohort Study.International journal of cancer · 2026Article
- The Role of KRAS in Non-Small Cell Lung Cancer: From Molecular Background to Precision Medicine.International journal of molecular sciences · 2026Review
- SMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma.Translational oncology · 2026Article
- Erythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort.Medicina (Kaunas, Lithuania) · 2026Article
- Loss-of-Function Mutations in SWI/SNF Complexes Associated With Active Tumour Immune Microenvironment Clinical Response to Immune Checkpoint Blockade.Journal of cellular and molecular medicine · 2026Article
- Genetic analysis of primary lung interdigitating dendritic cell sarcomas.The Journal of pathology · 2026Article
- Thoracic SMARCA4-Deficient Undifferentiated Tumor Presenting as a Giant Mediastinal Mass: A Case Report.The American journal of case reports · 2026Article
- Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers.Journal of medicinal chemistry · 2026Article
- Establishment and characterization of TRI-LC21: a novel patient-derived cell line of SMARCA4-deficient undifferentiated thoracic tumor.Human cell · 2026Article
- Histone Methylation and Chromatin Remodeling in Non-Small Cell Lung Cancer: Mechanisms of Oncogenesis and Emerging Therapeutic Strategies.Biomedicines · 2026Review
- Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies.MedComm · 2026Review
- Article
- The clinicopathologic characteristics and outcomes of uncommon KRAS mutations in patients with non-small cell lung cancer.Virchows Archiv : an international journal of pathology · 2026Article
- Bibliometric analysis and knowledge mapping of thoracic SMARCA4-deficient undifferentiated tumor.Discover oncology · 2026Article
- SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review.Journal of immunotherapy and precision oncology · 2026Review
- Clinicopathological characteristics of patients with inoperable non-small cell lung cancer harboring circulating NRF2 pathway mutations.The Journal of pathology · 2026Article
- Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B.NPJ precision oncology · 2026Article
154 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 4 institutions in 1 country.
Adam J SchoenfeldThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-2644-1416
Chai Bandlamudi *Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jessica A Lavery *Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2746-5647
Joseph Montecalvo *Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Azadeh Namakydoust *Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.
Hira RizviThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.
Jacklynn EggerDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2180-4169
Carla P ConcepcionDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Sonal PaulDepartment of Medicine, New York-Presbyterian Brooklyn Methodist Hospital - Weill Cornell Medicine, New York, New York.ORCID 0000-0002-2938-4488
Maria E ArcilaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Yahya DaneshbodDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jason ChangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jennifer L SauterDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6987-2294
Amanda BerasDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8811-6822
Marc LadanyiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Tyler JacksDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Charles M RudinThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.ORCID 0000-0001-5204-3465
Barry S TaylorCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Mark T A DonoghueCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Glenn HellerDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Matthew D HellmannThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-2670-9777
Natasha Rekhtman *Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. rielyg@mskcc.org rekhtman@mskcc.org.ORCID 0000-0001-5801-3144
Gregory J Riely *Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York. rielyg@mskcc.org rekhtman@mskcc.org.
Memorial Sloan Kettering Cancer Center · USHoward Hughes Medical Institute · USMassachusetts Institute of Technology · USNewYork–Presbyterian Brooklyn Methodist Hospital · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
purposeEXPERIMENTAL
designTo characterize
resultsIn 4,813 tumors from patients with NSCLC, we identified 8% (
conclusions
Indexed as
AgedAMP-Activated Protein Kinase KinasesCarcinoma, Non-Small-Cell LungDisease-Free SurvivalDNA HelicasesFemaleGene Expression Regulation, NeoplasticGenome, HumanGenomicsHumansImmunotherapyKelch-Like ECH-Associated Protein 1MaleMiddle AgedMutationNuclear ProteinsAMP-Activated Protein Kinase KinasesDNA HelicasesKEAP1 protein, humanKelch-Like ECH-Associated Protein 1KRAS protein, humanNuclear ProteinsProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)SMARCA4 protein, humanSTK11 protein, humanTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.